Acarbose/orlistat - Empros Pharma

Drug Profile

Acarbose/orlistat - Empros Pharma

Alternative Names: EMP-16-01

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Empros Pharma
  • Class
  • Mechanism of Action Amylase inhibitors; Lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 08 Aug 2016 Phase-II clinical trials in Obesity in Sweden (PO) (EudraCT2016-001055-50)
  • 08 Aug 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO) (EudraCT2016-001055-50)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top